



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
08/719,571	09/25/1996	DAVID J. ANDERSON	A-63899-1	9615
35437 75	90 05/28/2004		EXAMINER	
	N COHN FERRIS GLO	GRUN, JAMES LESLIE		
666 THIRD AVENUE NEW YORK, NY 10017			ART UNIT	PAPER NUMBER
11211 101111, 1			1641	

DATE MAILED: 05/28/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary		08/719,571	ANDERSON ET AL.				
		Examiner	Art Unit				
		James L Grun	1641				
	The MAILING DATE of this communication app	pears on the cover sheet with the c	orrespondence address				
Period for Reply							
THE I - Exter after - If the - If NC - Failu Any I	ORTENED STATUTORY PERIOD FOR REPL' MAILING DATE OF THIS COMMUNICATION. nsions of time may be available under the provisions of 37 CFR 1.1 SIX (6) MONTHS from the mailing date of this communication. period for reply specified above is less than thirty (30) days, a reply period for reply is specified above, the maximum statutory period or re to reply within the set or extended period for reply will, by statute reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be timy within the statutory minimum of thirty (30) day will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
1)[\]	Responsive to communication(s) filed on <u>18 Fe</u>	ebruary 2004.					
•		action is non-final.					
/—	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
-,	closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims						
-	4)⊠ Claim(s) <u>4-8 and 12-16</u> is/are pending in the application.						
•	4a) Of the above claim(s) is/are withdrawn from consideration.						
	5) Claim(s) is/are allowed.						
·	☑ Claim(s) <u>4-8 and 12-16</u> is/are rejected.						
7)	Claim(s) is/are objected to.						
8)	Claim(s) are subject to restriction and/or election requirement.						
Applicati	on Papers						
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority u	ınder 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
Attachment(s)							
1) Notice of References Cited (PTO-892) 4) Interview Summary (PTO-413) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) Paper No(s)/Mail Date							
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date 5) Notice of Informal Patent Application (PTO-152) 6) Other:							

Art Unit: 1641

To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Technology Center 1600, Group 1640, Art Unit 1641.

The amendment filed 18 February 2004 is acknowledged and has been entered. Claims 4-8 and 12-16 remain in the case.

The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

The specification is objected to under 35 U.S.C. § 112, first paragraph, as failing to provide an adequate written description of the invention, and failing to adequately teach how to make and/or use the invention, i.e. failing to provide an enabling disclosure.

Claims 4-8 and 12-16 are rejected, for the reasons of record, under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention, and which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

Applicant's arguments filed 18 February 2004 have been fully considered but they are not deemed to be persuasive. Applicant urges that neural stem cells are capable of symmetric, self-renewing division. This is not found persuasive because, although the instant neural RET+

Page 3

Application/Control Number: 08/719,571

Art Unit: 1641

progenitor cells may derive from some of the RET-LNGFR+ (p75+) neural stem cells (see e.g. Fig. 1), the capabilities of the precursor of the instantly isolated cell population are not germane to the issue of whether the written description enables any ability of one to select any subpopulations of the RET+ cell population with different particular lineage commitments for use. Applicant urges that the specification supports the identification of particular lineages which derive from the isolated RET+ cells. This is not found persuasive for the reasons of record. The ability of one to identify a particular differentiated cell subpopulation which derives from a precursor cell population and which may no longer express the marker used for the original isolation of the precursor cell population as a whole does not support any ability of one to select that subpopulation of cells, which were indistinguishable "by expression of any of the antigenic markers examined or by their morphology" from any other cell subpopulation of the originally isolated marker bearing precursor cell population as a whole, from the marker bearing precursor cell population as a whole as is now claimed. As set forth, in the absence of further written description and guidance from applicant, one would be unable to practice the invention as is now claimed.

Claims 8 and 16, and claims 13-14 as dependent from claim 16, are rejected under 35 U.S.C. § 102(b) as being clearly anticipated by Stemple et al. (Cell <u>71</u>: 973-985, 1992) for reasons of record.

Art Unit: 1641

Applicant's arguments filed 18 February 2004 have been fully considered but they are again not deemed to be persuasive for the reasons of record that there remains no factual evidence of a difference between what is disclosed in the reference and what is instantly claimed. As set forth, the cloned cells of the reference meet the limitations of the substantially pure population as instantly claimed. Applicant's arguments with regard to the different methods of isolation, i.e. "using the method of claim 15" as instantly recited rather than the antibody to LNGFR, cloning, and serial subcloning of the reference, are not dispositive of the issues because the process of making a product does not serve to limit or distinguish the same product made by another method from itself. Applicant's argument again appears drawn to the initially isolated population of the reference which is again not found germane or persuasive with regard to the cloned cells of the reference noted in the rejection. Further, with regard to claim 16 and claims dependent thereupon, applicant admits that at least some of the cells cloned with the method of Stemple et al. are also "Nps" (see e.g. specification page 26) which would inherently express RET. The examiner would note again, with regard to claim 8, the disclosure of the reference that cloned cells were obtained which produced only nonneuronal cells such as glial cells (e.g.: page 977, col. 2; Table 2 (G + O); Fig. 7A (G + O).

As the claims relate to isolation and enrichment of RET+ cells from the neural crest, their cell culture, and the characterization of the lineage commitment of the cultured cells, the following rejection remains applicable:

Art Unit: 1641

Claims 4-8 and 12-16 are rejected under 35 U.S.C. § 103(a) as being unpatentable over Lo et al. (Perspectives Dev. Neurobiol. 2: 191-201, 1994), Stemple et al. (Dev. Biol. 159: 12-23, 1993), Stemple et al. (Cell 71: 973-985, 1992), and Martucciello et al. for reasons of record.

Applicant's arguments filed 18 February 2004 have been fully considered but they are not deemed to be persuasive. In response to applicant's arguments that RET expression helps to identify particular lineages derived from neural crest stem cells, the fact that applicant has recognized another advantage which would flow naturally from following the suggestion of the prior art, i.e. that the isolation of the RET+ cells and further study of their lineage commitment by cell culture should be done, cannot be the basis for patentability when the differences would otherwise be obvious. See Ex parte Obiaya, 227 USPQ 58, 60 (Bd. Pat. App. & Inter. 1985). Applicant's argument that the speculative development chart in Fig. 6 of Lo et al. would teach away from the actual populations isolated is not found persuasive as the various cell populations are recited, in almost all of the instant claims, in the alternative and the reference of Lo et al. clearly teaches RET expression in the cells which should be isolated, i.e. autonomic progenitor cells such as the proliferating undifferentiated neural crest precursor cells or those in which the marker persists during stages of lineage commitment including progenitors of neuronal cells and, possibly, glial cells (see e.g. Fig. 6 and page 194). Notwithstanding applicant's arguments to the contrary, Lo et al. clearly teach RET expression as a valuable marker of relevant precursor cells. Applicant's arguments are drawn to the results of the lineage analysis, not to the method of isolation and cell culture of RET+ cells as claimed. Applicant's argument that the references of

Art Unit: 1641

Stemple et al. (1993), Stemple et al. (1992), and Martucciello et al. do not teach RET as a useful marker for neural progenitor cells is not found persuasive for the reasons of record in view of their combined teachings of known isolation methods and antibodies with the relied upon teachings of the reference of Lo et al. Again, an invention may be obvious under 35 U.S.C. § 103 even if a great amount of experimentation is required within the teachings of the prior art so long as that experimentation is within the abilities of one of ordinary skill in the art to carry out, i.e., it is routine.

No claim is allowed.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 C.F.R. § 1.136(a).

A SHORTENED STATUTORY PERIOD FOR REPLY TO THIS FINAL ACTION IS SET TO EXPIRE **THREE MONTHS** FROM THE MAILING DATE OF THIS ACTION. IN THE EVENT A FIRST REPLY IS FILED WITHIN **TWO MONTHS** OF THE MAILING DATE OF THIS FINAL ACTION AND THE ADVISORY ACTION IS NOT MAILED UNTIL AFTER THE END OF THE **THREE-MONTH** SHORTENED STATUTORY PERIOD, THEN THE SHORTENED STATUTORY PERIOD WILL EXPIRE ON THE DATE THE ADVISORY ACTION IS MAILED, AND ANY EXTENSION FEE PURSUANT TO 37 C.F.R. § 1.136(a) WILL BE CALCULATED FROM THE MAILING DATE OF THE ADVISORY ACTION. IN NO EVENT WILL THE STATUTORY PERIOD FOR REPLY EXPIRE LATER THAN **SIX MONTHS** FROM THE MAILING DATE OF THIS FINAL ACTION.

Art Unit: 1641

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James L. Grun, Ph.D., whose telephone number is (571) 272-0821. The examiner can normally be reached on weekdays from 9 a.m. to 5 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le, SPE, can be contacted at (571) 272-0823.

The phone numbers for official facsimile transmitted communications to TC 1600, Group 1640, are (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application, or requests to supply missing elements from Office communications, should be directed to the Group receptionist whose telephone number is (571) 272-1600.

James L. Grun, Ph.D. May 24, 2004

CHRISTOPHER L. CHIN PRIMARY EXAMINER GROUP 1800 /69/

Christoph L. Chin